Cantor Fitzgerald started coverage on shares of Advaxis Inc. (NASDAQ:ADXS) in a report released on Tuesday. The firm set a “buy” rating and a $19.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 121.96% from the stock’s current price.

ADXS has been the subject of several other reports. HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the stock a “buy” rating in a report on Tuesday, October 25th. Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research note on Thursday, August 25th. Finally, Barclays PLC increased their target price on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 3rd. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $23.67.

Analyst Recommendations for Advaxis (NASDAQ:ADXS)

Shares of Advaxis (NASDAQ:ADXS) traded down 3.82% during mid-day trading on Tuesday, reaching $8.56. The company had a trading volume of 825,315 shares. The stock has a 50 day moving average of $9.24 and a 200-day moving average of $9.85. Advaxis has a one year low of $5.21 and a one year high of $16.30. The firm’s market capitalization is $341.06 million.

TRADEMARK VIOLATION WARNING: This story was posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this story can be accessed at http://www.financial-market-news.com/advaxis-inc-adxs-research-coverage-started-at-cantor-fitzgerald/1209297/.

In other news, insider Gregory T. Mayes sold 19,162 shares of the firm’s stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $8.23, for a total transaction of $157,703.26. Following the sale, the insider now owns 103,087 shares in the company, valued at approximately $848,406.01. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel O’connor sold 8,240 shares of the firm’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $8.32, for a total transaction of $68,556.80. Following the sale, the chief executive officer now owns 303,127 shares in the company, valued at approximately $2,522,016.64. The disclosure for this sale can be found here. Insiders own 4.56% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Northern Capital Management LLC boosted its stake in Advaxis by 6.0% in the third quarter. Northern Capital Management LLC now owns 18,125 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 1,025 shares during the period. Swiss National Bank boosted its stake in Advaxis by 11.0% in the second quarter. Swiss National Bank now owns 53,500 shares of the biotechnology company’s stock valued at $433,000 after buying an additional 5,300 shares during the period. PNC Financial Services Group Inc. boosted its stake in Advaxis by 115.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,500 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 11,500 shares during the period. Bank of New York Mellon Corp boosted its stake in Advaxis by 10.4% in the second quarter. Bank of New York Mellon Corp now owns 164,368 shares of the biotechnology company’s stock valued at $1,330,000 after buying an additional 15,543 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in Advaxis by 210.8% in the first quarter. Squarepoint Ops LLC now owns 63,100 shares of the biotechnology company’s stock valued at $570,000 after buying an additional 42,800 shares during the period. Hedge funds and other institutional investors own 58.37% of the company’s stock.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

5 Day Chart for NASDAQ:ADXS

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.